KRYS
Krystal Biotech, Inc.NASDAQHealthcare$260.95+0.79%ClosedMarket Cap: $7.63B
As of 2026-04-06
Valuation
P/E (TTM)
37.24
PEG
0.29
P/B
6.19
P/S
19.60
EV/EBITDA
42.55
DCF Value
$577.66
FCF Yield
2.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.6%
Operating Margin
41.5%
Net Margin
52.6%
ROE
18.7%
ROA
15.4%
ROIC
13.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $107.1M | 89.8% | $44.4M | $51.4M | $1.70 | — |
| FY 2025 | $389.1M | 92.6% | $161.3M | $204.8M | $6.84 | — |
| Q3 2025 | $97.8M | 94.2% | $41.4M | $79.4M | $2.66 | — |
| Q2 2025 | $96.0M | 92.5% | $39.3M | $38.3M | $1.29 | — |
| Q1 2025 | $88.2M | 94.3% | $36.2M | $35.7M | $1.20 | — |
| Q4 2024 | $91.1M | 94.6% | $41.4M | $45.5M | $1.52 | — |
| FY 2024 | $290.5M | 93.1% | $65.7M | $89.2M | $3.00 | — |
| Q3 2024 | $83.8M | 92.0% | $22.4M | $27.2M | $0.91 | — |
| Q2 2024 | $70.3M | 91.5% | $8.6M | $15.6M | $0.53 | — |
| Q1 2024 | $45.3M | 94.7% | $-6.7M | $932.0K | $0.03 | — |
| Q4 2023 | $42.1M | 89.6% | $3.1M | $8.7M | $0.30 | — |
| FY 2023 | $50.7M | 93.9% | $-109.7M | $10.9M | $0.39 | — |